Genmab A/S (GMAB.CO) News
Follow Genmab A/S (GMAB.CO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
AbbVie/Genmab lymphoma drug combo cut progression or death risk by 51% in trial
AbbVie Inc and Genmab A/S said their combination treatment for patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL) reduced the risk of disease progression or death by 51% compared with R-CHOP alone. The s
EQUITY | Oct 05, 2026, 07:36 PM UTC
M
Genmab, AbbVie drug combo shows 51% lower risk of progression in lymphoma trial
The EPCORE DLBCL-2 trial showed that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% compared to R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients.
EQUITY | Oct 05, 2026, 06:50 PM UTC